Quanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare Conference
06/07/2023 - 04:00 PM
BILLERICA, Mass. --(BUSINESS WIRE)--
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs Annual Global Healthcare Conference on June 14, 2023 at 10:40 a.m., PT. The presentation will be available virtually and listeners can register here: https://cc.webcasts.com/gold006/061223a_js/?entity=12_GUSDLRC . The presentation will be available following the conference on Quanterix’s website here: ir.quanterix.com .
To learn more about Quanterix, visit www.quanterix.com/about . To learn more about Quanterix’s Simoa® technology, visit: https://www.quanterix.com/technology .
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts -based company at https://www.quanterix.com or follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005252/en/
Media:
quanterix@pancomm.com
Investor Relations:
ir@quanterix.com
Source: Quanterix Corporation
QTRX Rankings
#175 Ranked by Stock Gains
QTRX Stock Data
Industry
Testing Laboratories
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Pharmaceuticals: Major, Professional, Scientific, and Technical Services, Testing Laboratories
About QTRX
quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).
